Teva Pharmaceutical Industries Ltd. reported revenue of $4.1 billion in the first quarter of 2011, 12 percent up from the corresponding quarter of 2010. Sales in North America were $2.064 billion in the first quarter, 11% lower than the corresponding quarter.
Revenue for the first quarter was below the consensus of 20 top Wall Street analysts who had predicted revenue of $4.25 billion.
However, non-GAAP net profit of $936 million in the first quarter, up 13% from the corresponding quarter, did meet analysts' expectations. Earnings per share were up 14% to $1.04.